0001628280-26-029802
SEC filingMerck reported Q1 2026 revenue of $16.3B, a 4.9% increase, but swung to a net loss of $4.2B. This divergence reflects strong underlying commercial performance overshadowed by significant strategic transactions and portfolio transition costs.
The company reported a GAAP net loss of $4.2B, or -$1.72 per share, a sharp reversal from the $5.1B net income recorded in the same period last year. Gross profit was essentially flat at $12.1B compared to the prior year, resulting in a gross margin of 74.2%. The significant swing to a net loss suggests the impact of substantial one-time charges or strategic investments below the gross profit line. Management commentary indicates that the company is actively managing through a period of significant transition, with additional costs associated with restructuring activities included in cost of sales, SG&A, and R&D expenses.
Operational execution remained strong on the cash flow front. Net cash provided by operating activities increased to $3.9B in Q1 2026, up from $2.5B in the prior year period. After capital expenditures of $991M, the company generated $2.9B in free cash flow. This robust cash generation provides financial flexibility to fund strategic initiatives and navigate the current earnings volatility.
The filing highlights significant upcoming challenges that contextualize the current strategic moves. The company expects a significant decline in Januvia sales in the first half of 2026 and anticipates losing nearly all U.S. sales following the loss of market exclusivity in May 2026. Internationally, Keytruda pricing in EU markets continues to face pressure from the launch and reimbursement of new indications. Management acknowledged that these actions and anticipated future actions will continue to negatively affect sales and profits, underscoring the importance of pipeline execution and new product launches to sustain long-term growth.